Sanofi kills PhIII JAK2 inhibitor on safety grounds
This article was originally published in Scrip
Sanofi has called an immediate halt to all trials of fedratinib (SAR302503) following reports of neurological side-effects. The company had reported positive Phase III results for the JAK2 inhibitor in myelofibrosis earlier this year. Now, however, it says it is cancelling all plans for regulatory filings.